Soleno Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Soleno Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Rare disease specialist with validated lead program but facing elevated litigation risk and execution uncertainty in critical launch phase. While Soleno achieved a significant FDA approval and generated $98.7M in trailing revenue, recent class action investigations and short-seller allegations regarding VYKAT XR safety and pricing have created substantial legal.
What is Soleno Therapeutics, Inc.'s industry? Soleno Therapeutics, Inc. (soleno.life) operates in Biopharmaceutical - Rare Genetic Disorders / Specialty Therapeutics. AskCyborg classifies Soleno Therapeutics, Inc. under Biopharmaceutical - Rare Genetic Disorders / Specialty Therapeutics in its company registry.
Soleno Therapeutics is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for rare genetic disorders. The company achieved a major milestone with FDA approval of VYKAT™ XR (diazoxide...
Cyborg Score thesis
Rare disease specialist with validated lead program but facing elevated litigation risk and execution uncertainty in critical...
Read the full analyst-debate transcript →Get the Latest Soleno Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSoleno Therapeutics, Inc. Overview
Pro stress-test →Soleno Therapeutics is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for rare genetic disorders. The company achieved a major milestone with FDA approval of VYKAT™ XR (diazoxide choline extended-release tablets) for Prader-Willi Syndrome in early 2025, its first approved product designed to address hyperphagia (insatiable hunger), a debilitating symptom of this rare metabolic disorder.
Strategic Profile
Pro stress-test →Soleno maintains a focused pipeline strategy centered on rare metabolic and endocrine diseases, capitalizing on high unmet medical needs where treatment options are severely limited. The company leverages diazoxide chemistry to target KATP channels in multiple tissue types, providing a differentiated mechanism with potential applications across multiple rare disease indications beyond Prader-Willi Syndrome.
Competitive Landscape
Pro stress-test →Soleno operates in the ultra-rare disease space with limited direct competition for Prader-Willi Syndrome treatment. The rare disease therapeutic market is fragmented with few players addressing specific rare metabolic disorders. Competitors in broader rare disease and obesity-related indications include Novo Nordisk and Pfizer, but PWS represents a distinct niche with minimal existing treatment options.
Industry Context
Soleno Therapeutics, Inc. operates in Biopharmaceutical - Rare Genetic Disorders / Specialty Therapeutics.
Key facts
Founded: 1999 · Headquarters: Redwood City, California · Employees: 100-250 · Revenue: $98.7M · Market cap: $2.15B